ES2530769T3 - Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno - Google Patents

Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno Download PDF

Info

Publication number
ES2530769T3
ES2530769T3 ES95923042T ES95923042T ES2530769T3 ES 2530769 T3 ES2530769 T3 ES 2530769T3 ES 95923042 T ES95923042 T ES 95923042T ES 95923042 T ES95923042 T ES 95923042T ES 2530769 T3 ES2530769 T3 ES 2530769T3
Authority
ES
Spain
Prior art keywords
antigen
cells
vivo
activation
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95923042T
Other languages
English (en)
Inventor
Edgar G Engleman
Ronald Levy
Frank Hsu
Claudia Benike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2530769T3 publication Critical patent/ES2530769T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de células dendríticas humanas aisladas que se han pulsado con un antígeno in vitro en la producción de un medicamento para activar una respuesta inmunitaria a un antígeno en un paciente humano.
ES95923042T 1994-06-14 1995-06-13 Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno Expired - Lifetime ES2530769T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25977494A 1994-06-14 1994-06-14
PCT/US1995/007461 WO1995034638A1 (en) 1994-06-14 1995-06-13 Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Publications (1)

Publication Number Publication Date
ES2530769T3 true ES2530769T3 (es) 2015-03-05

Family

ID=22986324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95923042T Expired - Lifetime ES2530769T3 (es) 1994-06-14 1995-06-13 Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno

Country Status (8)

Country Link
EP (1) EP0765386B1 (es)
JP (1) JPH10504284A (es)
AU (1) AU710783B2 (es)
CA (1) CA2192655A1 (es)
DK (1) DK0765386T3 (es)
ES (1) ES2530769T3 (es)
PT (1) PT765386E (es)
WO (1) WO1995034638A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
JP2000508628A (ja) * 1996-03-22 2000-07-11 エール・ユニバーシティ 対象体内で免疫応答を誘導する方法
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6194204B1 (en) 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
CA2289742C (en) * 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
EP0983345A1 (en) 1997-05-21 2000-03-08 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6713250B1 (en) 1997-08-08 2004-03-30 The Research Foundation Of State University Of New York Identification of human allergens and T-lymphocyte antigens in vitro
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2775692B1 (fr) * 1998-03-03 2000-06-16 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
FR2782524B1 (fr) * 1998-08-21 2002-07-19 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
WO1999063050A2 (en) * 1998-06-02 1999-12-09 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
IT1312570B1 (it) * 1999-05-28 2002-04-22 Genera Spa Metodo per il traferimento di antigeni a cellule dendritiche.
WO2001040308A1 (en) * 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
DE102009017827A1 (de) * 2009-04-20 2010-10-21 Sasol Germany Gmbh Verfahren zur Herstellung von verzweigten Kohlenwasserstoffen aus Fettalkoholen und Verwendung derartig hergestellter Kohlenwasserstoffe
BRPI0905536A2 (pt) * 2009-12-16 2011-08-16 Fundacao De Amparo A Pesquisa processo de maturação de células dendrìticas autólogas
JP5995247B2 (ja) 2011-02-23 2016-09-21 国立大学法人京都大学 多能性幹細胞から樹状細胞を製造する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells

Also Published As

Publication number Publication date
WO1995034638A1 (en) 1995-12-21
DK0765386T3 (en) 2015-01-26
CA2192655A1 (en) 1995-12-21
EP0765386B1 (en) 2014-12-10
EP0765386A4 (en) 1998-01-07
PT765386E (pt) 2015-02-06
AU710783B2 (en) 1999-09-30
JPH10504284A (ja) 1998-04-28
AU2772595A (en) 1996-01-05
EP0765386A1 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ES2099056T3 (es) Cepas de lactobacillus de origen humano, sus composiciones y usos de las mismas.
EA199800946A1 (ru) Концентрированный препарат антител
GEP20022648B (en) Method for Inducing T Cell Tolerance to a Tissue or Organ Graft
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
NO331101B1 (no) In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.
ES2053815T3 (es) Preparacion farmaceutica con liberacion prolongada de una dihidropiridina y un antagonista de un beta-adrenorreceptor y un procedimiento para su preparacion.
ES2142829T3 (es) Dispositivos para llevar a cabo un procedimiento intraluminal.
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
ATE491465T1 (de) Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
SE9003718D0 (sv) Implantat med genomgaaende passage
FI870808L (fi) 9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
ATE422893T1 (de) Mannose-rezeptor tragende zellinie und antigen zusammensetzung
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
IL122755A0 (en) Preparations and methods for the treatment of T cell mediated diseases
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.